- Home
- FMTO vs GLMD Comparison
FMTO vs GLMD Comparison
Compare FMTO & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMTO
- GLMD
- Stock Information
- Founded
- FMTO 2000
- GLMD 2000
- Country
- FMTO Israel
- GLMD Israel
- Employees
- FMTO N/A
- GLMD N/A
- Industry
- FMTO
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- FMTO
- GLMD Health Care
- Exchange
- FMTO NYSE
- GLMD Nasdaq
- Market Cap
- FMTO 3.0M
- GLMD 3.0M
- IPO Year
- FMTO N/A
- GLMD 2014
- Fundamental
- Price
- FMTO $4.60
- GLMD $1.51
- Analyst Decision
- FMTO
- GLMD Hold
- Analyst Count
- FMTO 0
- GLMD 1
- Target Price
- FMTO N/A
- GLMD N/A
- AVG Volume (30 Days)
- FMTO 35.5K
- GLMD 255.6K
- Earning Date
- FMTO 08-06-2025
- GLMD 06-17-2025
- Dividend Yield
- FMTO N/A
- GLMD N/A
- EPS Growth
- FMTO N/A
- GLMD N/A
- EPS
- FMTO N/A
- GLMD N/A
- Revenue
- FMTO $620,978.00
- GLMD N/A
- Revenue This Year
- FMTO N/A
- GLMD N/A
- Revenue Next Year
- FMTO N/A
- GLMD N/A
- P/E Ratio
- FMTO N/A
- GLMD N/A
- Revenue Growth
- FMTO N/A
- GLMD N/A
- 52 Week Low
- FMTO $3.85
- GLMD $1.15
- 52 Week High
- FMTO $6,927.50
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- FMTO N/A
- GLMD 56.28
- Support Level
- FMTO N/A
- GLMD $1.36
- Resistance Level
- FMTO N/A
- GLMD $1.60
- Average True Range (ATR)
- FMTO 0.00
- GLMD 0.09
- MACD
- FMTO 0.00
- GLMD 0.03
- Stochastic Oscillator
- FMTO 0.00
- GLMD 79.07
About FMTO FEMTO TECHNOLOGIES INC
Femto Technologies Inc is an integrated software company. It owns and markets Benefit CRM, a proprietary customer relationship management CRM software product enabling small and medium sized businesses to optimize their day to day business activities such as sales management, personnel management, marketing, call center activities, and asset management.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.